Technical Data Sheet
Retatrutide
Also Known As: LY-3437943, Triple-G, Retatrutide peptide, LY3437943, Triple agonist obesity drug, GIP GLP-1 glucagon triple agonist, Eli Lilly triple agonist, Triple incretin agonist, Retatrutide LY3437943, Tri-agonist obesity peptide, triple agonist, GLP-1/GIP/GCG, glucagon receptor, reta, ret
Scan To View Profile
| Evidence Tier | Investigational |
|---|---|
| Category | Weight Loss & Metabolism |
| Class | Synthetic triple agonist: GIP receptor + GLP-1 receptor + glucagon receptor |
| Molecular Target | GIPR (GIP receptor) + GLP-1R (GLP-1 receptor) + GCGR (glucagon receptor); triple incretin/glucagon signaling for maximal metabolic effect |
| Sequence | 39-aa GIP/GLP-1/glucagon tri-agonist (acylated) |
| Molecular Weight | ~4731 Da |
| CAS | 2381089-83-2 |
| Parent | Incretin triple agonist |
| Mechanism | It activates three different hormone receptors at once (GLP-1, GIP, and Glucagon). This not only halts appetite but forcefully increases the body's baseline calorie burn rate. |
| Studied For | Obesity / overweight, Type 2 diabetes, Liver fat / MASLD / NAFLD, Triple agonist weight loss, GLP-1 GIP glucagon combined therapy, Metabolic syndrome, Insulin resistance, HbA1c reduction, Cardiovascular risk reduction, Non-alcoholic steatohepatitis (NASH), Body weight reduction vs placebo, Appetite suppression triple pathway, Lean mass preservation during weight loss, Obstructive sleep apnea in obesity, extreme weight loss, obesity, liver fat reduction, NAFLD, metabolic rate increase, appetite suppression, lipid lowering |
| Administration Route | Injection Only |
| Form | lyophilized |
| Diluent | bacteriostatic or sterile water; gentle |
| Storage Temperature | frozen/refrigerated, dark |
| Light Sensitive | Yes |
| Freeze / Thaw | avoid |
| Reconstituted Shelf Life | 28 Days |
| Handling Notes | Lipidated peptide; gentle reconstitution avoids foaming. |
| Regulatory | Investigational (Eli Lilly); Phase 3 TRIUMPH program -- TRIUMPH-1 topline results reported May 2026 (2,339 participants, 80 wk; -28.3% mean weight loss at 12 mg; all three doses met primary and key secondary endpoints vs placebo). TRIUMPH-2 (obesity/overweight with type 2 diabetes) and TRIUMPH-3 (severe obesity with established cardiovascular disease) both met their primary endpoints, announced 23 July 2026, with 20.8 to 22.6 percent mean weight loss at 80 weeks. As of 2 September 2026 no marketing application has been filed. Sponsor guidance was revised on 23 July 2026: Lilly now plans a Biologics License Application for obesity in the first quarter of 2027, superseding earlier second-half-of-2026 guidance; an FDA decision is not expected before late 2027. FDA has granted Fast Track designation for obesity. Not FDA-approved; non-trial material is research-use-only. Not on the WADA 2026 Prohibited List. |
| Sources |